Meanwhile, the combination of RC48 with other targeted drugs or chemotherapeutic agents might be a promising therapeutic strategy for the treatment of advanced HER2-positive GC and is expected to achieve more favorable results in the future. The gene discussed is ERBB2; the disease is gastric cancer.